• Publications
  • Influence
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
TLDR
With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases. Expand
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
TLDR
Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases and an algorithm for patient management to maintain bone health is recommended. Expand
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
TLDR
The bone resorption marker Ntx provides valuable prognostic information in patients with bone metastases receiving bisphosphonates, and showed some correlation with risk of negative clinical outcomes. Expand
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
TLDR
A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days, and the effect diminished progressively through follow-up. Expand
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
TLDR
Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer. Expand
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
TLDR
An interdisciplinary expert panel of clinical oncologists and of specialists in metabolic bone diseases assessed the widespread evidence and information on the efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of BP and recommends amino-bisphosphonates for patients with metastatic bone disease from breast cancer and zoledronic acid for Patients with other solid tumours as primary disease. Expand
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer
TLDR
The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhu MAb Her2 alone. Expand
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
PURPOSE To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective roleExpand
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
TLDR
Among patients with elevated UNTx despite ongoing IV BP therapy, denosumab normalized uNTx levels more frequently than the continuation of IV BP, and fewer patients receiving denosUMab experienced on-study SREs than those receiving IV BPs. Expand
Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma
The objective of this study was to assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to renal cell carcinoma (RCC).
...
1
2
3
4
5
...